Literature DB >> 26615015

[The clinical utility of C-peptide measurement in diabetology].

Ewa Otto-Buczkowska1.   

Abstract

C-peptide is produced in equal amounts to insulin and is the best measure of endogenous insulin secretion in patients with diabetes. Measurement of insulin secretion using C-peptide can be helpful in clinical practice: differences in insulin secretion are fundamental to different requirements in the treatment of diabetes. An important clinical role of C-peptide is differentiating between type 1 and type 2 diabetes. Low basal C-peptide can be considered as criterion for transferring the patients, initially diagnosed as type 2 diabetes, in the type 1 diabetes group. C-peptide level may be a good predictor of the clinical partial remission during the first year of type 1 diabetes. Latent autoimmune diabetes in adults (LADA) is a special form of diabetes that is clinically similar to type 2 diabetes but with positivity for pancreatic autoantibodies and lower C-peptide levels. The measurement of C-peptide level and of immunological markers may represent important additional tools for establishing the correct diagnosis. The natural course of these patients shows that C-peptide will decrease with time in parallel with the curve for C-peptide in classical type 1 diabetic patients. Persistence of C-peptide is an important clinical feature of MODY. It is particularly important to identify these patients as they are commonly misdiagnosed as type 1 diabetes and treated with insulin, C-peptide can be used to assist in patient selection for islet cell transplantation and post-transplant monitoring. High uncorrected fasting C-peptid in the presence of hyperglycemia may suggest insulin resistance. © Polish Society for Pediatric Endocrinology and Diabetology.

Entities:  

Keywords:  C-peptide; diabetes type; insulin secretion

Mesh:

Substances:

Year:  2015        PMID: 26615015     DOI: 10.18544/PEDM-20.02.0004

Source DB:  PubMed          Journal:  Pediatr Endocrinol Diabetes Metab        ISSN: 2083-8441


  1 in total

1.  Protective Effect of Liposomal Epigallocatechin-Gallate in Experimental Gentamicin-Induced Hepatotoxicity.

Authors:  Adriana Elena Bulboacă; Alina Silvia Porfire; Vasile Rus; Cristina Ariadna Nicula; Corneliu Angelo Bulboacă; Sorana D Bolboacă
Journal:  Antioxidants (Basel)       Date:  2022-02-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.